Urinary loss of erythropoietin after intravenous versus subcutaneous epoetin-beta in preterm infants.
Hematopoietic and non-hematopoietic effects of recombinant erythropoietin (Epo) given to preterm infants are controversially discussed. Because renal loss of Epo was significantly higher after intravenous versus subcutaneous Epoetin-beta administration, we suggest a reconsideration of whether subcutaneous recombinant Epo is more efficient and safer because of lower peaks of circulating Epo.
Langer
Juliane
J
Klinik für Neonatologie, Campus Virchow-Klinikum, Charité-Universitätsmedizin, Berlin, Germany.
Obladen
Michael
M
Dame
Christof
C
D000751:Anemia, Neonatal / Q000188:drug therapy* / Q000652:urine*; D004921:Erythropoietin / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000188:drug therapy* / Q000652:urine*; D019102:Infant, Very Low Birth Weight; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008137:Longitudinal Studies; D011994:Recombinant Proteins
D011994:Recombinant Proteins; C103998:epoetin beta; D004921:Erythropoietin